Breast cancer is responsible for most of the cancer-induced deaths in women around the world. The current review will discuss different approaches of targeting HER2, an epidermal growth factor overexpressed in 30% of breast cancer cases.
Data sources
We conducted a search on Pubmed and Scopus databases to find studies relevant to HER2+ breast cancers and targeting HER2 as means of immunotherapy. Out of 1043 articles, 105 studies were included in this review.
Data summary
As well as the introduction of HER2 and breast cancer subtypes, we discussed various aspects of HER2-targeting immunotherapy including monoclonal antibodies, Antibody-drug conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cells and vaccines.
Conclusions
Despite several ways of controlling breast cancer, the need to investigate new drugs and approaches seems to be much significant as this cancer still has a heavy burden on people’s health and survival.
BrayFFerlayJSoerjomataramI, et al.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2018;
68: 394–424.
2.
SiegelRLMillerKDJemalA.Cancer statistics, 2019. CA A Cancer J Clin2019;
69: 7–34.
3.
EliyatkinNYalcinEZengelB, et al.
Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breast Health2015;
11: 59–66.
4.
IshikawaTIchikawaYShimizuD, et al.
The role of HER-2 in breast cancer. J Surg Sci2014;
2: 4–9.
5.
MenardSPupaSMCampiglioM, et al.
Biologic and therapeutic role of HER2 in cancer. Oncogene2003;
22: 6570–6578.
6.
IqbalNIqbalN.Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int2014;
2014: 852748.
7.
NounouMIElamrawyFAhmedN, et al.
Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl)2015;
9: 17–34.
8.
KaylAEMeyersCA.Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol2006;
18: 24–28.
9.
DisisMLStantonSE.Immunotherapy in breast cancer: an introduction. Breast2018;
37: 196–199.
10.
Al-AwadhiALee MurrayJIbrahimNK.Developing anti-HER2 vaccines: breast cancer experience. Int J Cancer2018;
143: 2126–2132.
11.
WangJZhouP.New approaches in CAR-T cell immunotherapy for breast cancer. Adv Exp Med Biol2017;
1026: 371–381.
12.
BeckAGoetschLDumontetC, et al.
Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov2017;
16: 315–337.
13.
PondeNBrandaoMEl-HachemG, et al.
Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev2018;
67: 10–20.
14.
Patrick GL. An Introduction to Medicinal Chemistry. United Kingdom. OUP Oxford. 2013.
15.
RoskoskiRJr.The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res2014;
79: 34–74.
16.
Brandt-RaufPWPincusMRCarneyWP.The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog1994;
5: 313–329.
17.
MitriZConstantineTO'reganR.The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract2012;
2012: 743193.
18.
DesmedtCHaibe-KainsBWirapatiP, et al.
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res2008;
14: 5158–5165.
19.
PusztaiLMazouniCAndersonK, et al.
Molecular classification of breast cancer: limitations and potential. Oncologist2006;
11: 868–877.
20.
DaiXLiTBaiZ, et al.
Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res2015;
5: 2929–2943.
21.
VallejosCSGomezHLCruzWR, et al.
Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clinical Breast Cancer2010;
10: 294–300.
22.
Barroso-SousaRSilvaDDAlessiJV, et al.
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. Ecancermedicalscience2016;
10: 609.
23.
RugoHSVidulaNMaC.Improving response to hormone therapy in breast cancer: new targets, new therapeutic options. Am Soc Clin Oncol Educ Book2016;
35: e40-54–e54.
24.
SorlieTPerouCMTibshiraniR, et al.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA2001;
98: 10869–10874.
25.
NishimuraROsakoTOkumuraY, et al.
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med2010;
1: 747–754.
26.
RakhaEAReis-FilhoJSEllisIO.Basal-like breast cancer: a critical review. J Clin Oncol2008;
26: 2568–2581.
27.
BrentonJDCareyLAAhmedAACaldasC.Molecular classification and molecular forecasting of breast cancer: ready for clinical application?J Clin Oncol2005;
23: 7350–7360.
28.
Garnock-JonesKPKeatingGMScottLJ.Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs2010;
70: 215–239.
29.
DillmanRO.Perceptions of herceptin: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm1999;
14: 5–10.
30.
CobleighMAVogelCLTripathyD, et al.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol1999;
17: 2639–2648.
31.
MetroGMottoleseMFabiA.HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother2008;
9: 2583–2601.
32.
SlamonDJLeyland-JonesBShakS, et al.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med2001;
344: 783–792.
33.
LabidiSMejriNLaghaA, et al.
Targeted therapies in HER2-overexpressing metastatic breast cancer. Breast Care (Basel)2016;
11: 418–422.
34.
SeidmanAHudisCPierriMK, et al.
Cardiac dysfunction in the trastuzumab clinical trials experience. JCO2002;
20: 1215–1221.
35.
MaximianoSMagalhaesPGuerreiroMP, et al.
Trastuzumab in the treatment of breast cancer. BioDrugs2016;
30: 75–86.
36.
IshizunaKNinomiyaJOgawaT, et al.
Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report. J Med Case Rep2014;
8: 417–417.
37.
Luque-CabalMGarcía-TeijidoPFernández-PérezY, et al.
Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol2016;
10: 21–30.
38.
TuralDAkarEMutluH, et al.
P95 HER2 fragments and breast cancer outcome. Expert Rev Anticancer Ther2014;
14: 1089–1096.
39.
PohlmannPRMayerIAMernaughR.Resistance to trastuzumab in breast cancer. Clin Cancer Res2009;
15: 7479–7491.
40.
NagataYLanKHZhouX, et al.
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell2004;
6: 117–127.
41.
FiszmanGLJasnisMA.Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int J Breast Cancer2011;
2011: 352182–352182.
42.
MortensonEDFuY-X.Adaptive immune responses and HER2/neu positive breast cancer. Curr Pathobiol Rep2013;
1: 37–42.
43.
OsakoTNishimuraRNishiyamaY, et al.
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan. Mol Clin Oncol2015;
3: 1268–1274.
44.
PatelRBatesJS.Pertuzumab in metastatic breast cancer. J Adv Pract Oncol2012;
3: 391–394.
45.
CapelanMPuglianoLDe AzambujaE, et al.
Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol2013;
24: 273–282.
46.
BaselgaJGelmonKAVermaS, et al.
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol2010;
28: 1138–1144.
47.
SchneeweissAChiaSHickishT, et al.
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol2013;
24: 2278–2284.
48.
CeranCCokolMCingozS, et al.
Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-alpha. BMC Cancer2012;
12: 450.
49.
MayerIADentRTanT, et al.
Novel targeted agents and immunotherapy in breast cancer. Am Soc Clin Oncol Educ Book2017;
37: 65–75.
50.
PerezHLCardarelliPMDeshpandeS, et al.
Antibody-drug conjugates: current status and future directions. Drug Discov Today2014;
19: 869–881.
51.
Tsuchikama K and An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 2018; 9: 33–46. https://doi.org/10.1007/s13238-016-0323-0
52.
LambertJMMorrisCQ.Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv Ther2017;
34: 1015–1035.
53.
ChalouniCDollS.Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res2018;
37: 20–20.
54.
MecklenburgL.A brief introduction to antibody-drug conjugates for toxicologic pathologists. Toxicol Pathol2018;
46: 746–752.
55.
DanNSetuaSKashyapVK, et al.
Antibody-drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel, Switzerland)2018;
11: 32.
56.
VermaSMilesDGianniL, et al.
Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med2012;
367: 1783–1791.
57.
KropIEKimSBGonzalez-MartinA, et al.
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol2014;
15: 689–699.
58.
LorussoPMWeissDGuardinoE, et al.
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res2011;
17: 6437–6447.
59.
Von MinckwitzGHuangCSManoMS, et al.
Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med2019;
380: 617–628.
60.
HodgesLMMarkovaSMChinnLW, et al.
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genom2011;
21: 152–161.
61.
LiGGuoJShenBQ, et al.
Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther2018;
17: 1441–1453.
62.
Rios-LuciCGarcia-AlonsoSDiaz-RodriguezE, et al.
Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res2017;
77: 4639–4651.
63.
TrailPADubowchikGMLowingerTB.Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacol Ther2018;
181: 126–142.
64.
RinnerthalerGGampenriederSPGreilR.HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer. IJMS2019;
20: 1115.
65.
Le JoncourVMartinsAPuhkaM, et al.
A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine. Mol Cancer Ther2019;
18: 1721–1730.
66.
FariaMPeayMLamB, et al.
Multiplex LC-MS/MS assays for clinical bioanalysis of MEDI4276, an antibody-drug conjugate of tubulysin analogue attached via cleavable linker to a biparatopic humanized antibody against HER-2. Antibodies (Basel)2019;
8: 11.
67.
PondeNAftimosPPiccartM.Antibody-drug conjugates in breast cancer: a comprehensive review. Curr Treat Options Oncol2019;
20: 37.
68.
SaitoYA.The role of genetics in IBS. Gastroenterol Clin North Am2011;
40: 45–67.
69.
TamuraKTsurutaniJTakahashiS, et al.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol2019;
20: 816–826.
70.
Pernas S and Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 2019; 11: 1758835919833519. doi: 10.1177/1758835919833519. PMID: 30911337; PMCID: PMC6425535.
HanXWangYHanW-D.Chimeric antigen receptor modified T-cells for cancer treatment. Chronic Dis Transl Med2018;
4: 225–243.
73.
MardianaSJohnLBHendersonMA, et al.
A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells. Cancer Res2017;
77: 1296–1309.
74.
AlmåsbakHAarvakTVemuriMC.CAR T cell therapy: a game changer in cancer treatment. J Immunol Res2016;
2016: 5474602.
75.
PetersenCTKrenciuteG.Next generation CAR T cells for the immunotherapy of high-grade glioma. Front Oncol2019;
9: 69.
76.
GrossGWaksTEshharZ.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA1989;
86: 10024–10028.
77.
KershawMHWestwoodJAParkerLL, et al.
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res2006;
12: 6106–6115.
78.
SalmikangasPKinsellaNChamberlainP.Chimeric antigen receptor T-cells (CAR T-cells) for cancer Immunotherapy – moving target for industry?Pharm Res2018;
35: 152.
79.
YuSYiMQinS, et al.
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer2019;
18: 125–125.
80.
TariqSMHaiderSAHasanM, et al.
Chimeric antigen receptor T-cell therapy: a beacon of hope in the fight against cancer. Cureus2018;
10: e3486–e3486.
81.
FeinsSKongWWilliamsEF, et al.
An introduction to chimeric antigen receptor (CAR) T cell immunotherapy for human cancer. Am J Hematol2019;
94(S1): S3–S9.
82.
SunMShiHLiuC, et al.
Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res2014;
16: R61.
83.
MunisvaradassRKumarSGovindasamyC, et al.
Human CD3+ T-Cells with the anti-ERBB2 chimeric antigen receptor exhibit efficient targeting and induce apoptosis in ERBB2 overexpressing breast cancer cells. IJMS2017;
18: 1797.
84.
SchönfeldKSahmCZhangC, et al.
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther2015;
23: 330–338.
85.
LiuHYangBSunT, et al.
Specific growth inhibition of ErbB2expressing human breast cancer cells by genetically modified NK92 cells. Oncol Rep2015;
33: 95–102.
86.
KershawMHJacksonJTHaynesNM, et al.
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol2004;
173: 2143–2150.
87.
MoritzDWelsWMatternJ, et al.
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA1994;
91: 4318–4322.
88.
StancovskiISchindlerDGWaksT, et al.
Targeting of T lymphocytes to neu/HER2-expressing cells using chimeric single chain Fv receptors. Journal of Immunology (Baltimore, MD: 1950)1993;
151: 6577–6582.
89.
CostaRLBSolimanHCzernieckiBJ.The clinical development of vaccines for HER2(+) breast cancer: current landscape and future perspectives. Cancer Treat Rev2017;
61: 107–115.
90.
LowenfeldLMickRDattaJ, et al.
Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial. Clin Cancer Res2017;
23: 2961–2971.
91.
SharmaAKoldovskyUXuS, et al.
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer2012;
118: 4354–4362.
92.
MittendorfEACliftonGTHolmesJP, et al.
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US military cancer institute clinical trials group study I-01 and I-02. Cancer2012;
118: 2594–2602.
93.
HolmesJPGatesJDBenavidesLC, et al.
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US military cancer institute clinical trials group study I-01 and I-02. Cancer2008;
113: 1666–1675.
94.
BenavidesLCGatesJDCarmichaelMG, et al.
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military cancer institute clinical trials group study I-01 and I-02. Clin Cancer Res2009;
15: 2895–2904.
95.
HolmesJPBenavidesLCGatesJD, et al.
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol2008;
26: 3426–3433.
96.
MittendorfEAArdavanisALittonJK, et al.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget2016;
7: 66192–66201.
97.
KnutsonKLSchiffmanKDisisML.Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest2001;
107: 477–484.
98.
LinehanDCGoedegebuurePSPeoplesGE, et al.
Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. Journal of Immunology (Baltimore, MD: 1950)1995;
155: 4486–4491.
99.
CliveKSTylerJACliftonGT, et al.
The GP2 peptide: a HER2/neu-based breast cancer vaccine. J Surg Oncol2012;
105: 452–458.
100.
WangWLiYWangY, et al.
Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine. Int Immunopharmacol2018;
54: 95–102.
101.
ParkJWMeliskoMEEssermanLJ, et al.
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol2007;
25: 3680–3687.
102.
LadjemiMZJacotWChardesT, et al.
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother2010;
59: 1295–1312.
103.
YangBJeangJYangA, et al.
DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother2014;
10: 3153–3164.
